Centre for Physical Activity Research (CFAS)

Medicine & Life Sciences

1. Exercise 100%
2. Type 2 Diabetes Mellitus 68%
3. Randomized Controlled Trials 38%
4. Asthma 36%
5. Skeletal Muscle 36%
6. Glucose 35%
7. Muscles 31%
8. Insulin 27%
9. Insulin Resistance 26%
10. Interleukin-6 25%
11. Inflammation 23%
12. Brown Adipose Tissue 23%
13. Adipose Tissue 22%
14. Cardiorespiratory Fitness 21%
15. Fats 20%
16. Cohort Studies 20%
17. Chronic Obstructive Pulmonary Disease 19%
18. Coronavirus 18%
19. Obesity 17%
20. Fasting 15%
21. Systematic Reviews 14%
22. Body Composition 14%
23. Life Style 14%
24. Metformin 14%
25. Cross-Over Studies 14%
26. Mortality 14%
27. Endurance Training 14%
28. Homeostasis 14%
29. Meta-Analysis 14%
30. Neoplasms 14%
31. Therapeutics 14%
32. fibroblast growth factor 21 13%
33. High-Intensity Interval Training 12%
34. Walking 12%
35. Resistance Training 12%
36. Adipocytes 12%
37. Bed Rest 12%
38. HIV 12%
39. Brown Adipocytes 11%
40. Athletes 11%
41. Liver 11%
42. Natural Killer Cells 11%
43. Glucose Tolerance Test 11%
44. Thermogenesis 10%
45. Glucagon 10%
46. White Adipose Tissue 10%
47. Cross-Sectional Studies 10%
48. Cytokines 10%
49. Glucagon-Like Peptide 1 10%
50. Biomarkers 10%
51. C-Reactive Protein 10%
52. Placebos 10%
53. Denmark 9%
54. Quality of Life 9%
55. Intra-Abdominal Fat 9%
56. Hormones 9%
57. Low Birth Weight Infant 9%
58. Interleukin-6 Receptors 9%
59. Cardiovascular Diseases 9%
60. Follistatin 8%
61. Skeletal Muscle Fibers 8%
62. Healthy Volunteers 8%
63. Muscle Cells 8%
64. Prediabetic State 8%
65. Health 8%
66. Sedentary Behavior 8%
67. Confidence Intervals 8%
68. Stem Cells 8%
69. Hemoglobins 8%
70. tocilizumab 8%
71. Myoblasts 8%
72. Prostatic Neoplasms 8%
73. Cancer Survivors 8%
74. Erythropoietin 7%
75. Ovariectomy 7%
76. Hypoxia 7%
77. Pneumonia 7%
78. Prospective Studies 7%
79. Fatty Acids 7%
80. Tanzania 7%
81. Running 7%
82. Leg 7%
83. Adult Respiratory Distress Syndrome 7%
84. Phenotype 7%
85. Tumor Necrosis Factor-alpha 6%
86. Oxidative Stress 6%
87. Child 6%
88. Pulmonary Diffusing Capacity 6%
89. Arterial Pressure 6%
90. Anti-Inflammatory Agents 6%
91. 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol 6%
92. Lipid Metabolism 6%
93. Metabolic Diseases 6%
94. Epigenomics 6%
95. Adipokines 6%
96. Comorbidity 6%
97. Population 6%
98. repaglinide 6%
99. Metabolic Syndrome 6%
100. Smartphone 6%